New research suggests cystic fibrosis transmembrane conductance regulator (CFTR) modulators may provide mental health benefits for pediatric patients and their caregivers early in treatment.
New research suggests cystic fibrosis transmembrane conductance regulator (CFTR) modulators may provide mental health benefits for pediatric patients and their caregivers early in treatment.
Read More
Combining formoterol and methacholine significantly improves mucociliary clearance in animal models of cystic fibrosis, compared to using either drug alone.
Read More
A 28-year-old cystic fibrosis patient underwent a 36-hour quadruple organ transplant for both lungs, a liver, and a kidney from a single donor.
Read More
New research indicates that baseline lung health is a stronger predictor of SARS-CoV-2 outcomes in cystic fibrosis transplantation patients than the time elapsed since transplantation.
Read More
New label extensions for Alyftrek and Trikafta make approximately 95% of the cystic fibrosis population in the United States eligible for treatment.
Read More
Researchers developed lipid nanoparticles capable of inserting a full healthy CFTR gene into lab-grown human airway cells with severe cystic fibrosis.
Read More
The Quantitative Mucin Index (MUCQ) of the Lung analyzes sputum and other lung mucus samples to detect airway mucus abnormalities, assess disease risk, and track disease progression in patients over time.
Read More
Researchers assessed salt intake in cystic fibrosis patients undergoing treatment with CFTR modulators, which improve salt conservation and other physiological markers.
Read More
A new report shows steady progress in identifying cystic fibrosis earlier, with 67% of CF infants screened in 2024 within the first 28 days of life, compared to 60% in 2014.
Read More
UK patients with cystic fibrosis are being hit hard by a wave of influenza in the country.
Read More
A new drug delivery system transports genetic therapies directly to the lungs, opening promising possibilities for patients with conditions like lung cancer and cystic fibrosis.
Read More
England’s National Institute for Health and Care Excellence issued a positive final draft recommendation for Vertex Pharma’s Alyftrek CFTR modulator, which will now be available via the National Health Service (NHS).
Read More
Alyftrek is a triple combination CFTR modulator comprised of deutivacaftor, tezacaftor and vanzacaftor.
Read More
A closer look at suction and secretion clearance devices from ABM Respiratory, Baxter, Neotech, Philips, Precision Medical, Sentec, Seoil Pacific, and Tactile Medical.
Read More
Phage therapy—the use of viruses, or phages, to target and kill bacteria—improved lung function and reduced sputum P. aeruginosa in patients with cystic fibrosis.
Read More
Changes in lung function are of critical importance to patients with cystic fibrosis (CF), as lung function is a key indicator of disease progression and treatment effectiveness.
Read More
The CF Foundation’s Newborn Screening Committee developed a consensus guideline with seven recommendations to describe current best practices in newborn screening nationwide.
Read More
Funding from the Cystic Fibrosis Foundation will support development of a breath test to diagnose Pseudomonas aeruginosa infections in CF patients.
Read More
Researchers say a CF diagnosis within 10 days of birth compared to diagnosis within 6 weeks of birth can produce better height and weight outcomes.
Read More
Cystic fibrosis patients with elevated levels of bacteria infected by Pf phage in their sputum experience a faster decline in lung function.
Read More
The FDA approved Alyftrek, a once-daily triple combo CFTR modulator, for certain cystic fibrosis patients aged 6 and older.
Read More
The Cystic Fibrosis Foundation is funding the development of a gene editing therapy that is designed to use ReCode’s tissue-specific delivery vehicle to transport gene editing cargo to the lung cells in people with cystic fibrosis.
Read More
Adherence to airway clearance therapy in the home is crucial for managing chronic lung conditions, but challenges like time constraints and lack of perceived benefit can hinder patient compliance. Experts offer strategies and new technologies to help improve patients’ adherence.
Read More
ETD001 aims to improve lung function by targeting mucus clearance in patients with high unmet medical needs.
Read More
